Identity and synonyms
Identity follows the supplied name and synonyms; no additional identity description is supplied.
Synonyms: NS2330
Nonpeptide agent · Nonpeptide small molecule
Detailed molecular class: Non-peptide monoamine reuptake inhibitor
Supplied sequence or chemical reference
PubChem CID: 11370864
Molecular formula: C17H23Cl2NO
IUPAC: (1R,2R,3S,5S)-3-(3,4-dichlorophenyl)-2-(ethoxymethyl)-8-methyl-8-azabicyclo[3.2.1]octane
Source: PC-TESOFENSINE
Database chemical reference; does not certify supplier vial, salt, isomer or formulation.
Mechanism
Inhibits noradrenaline, dopamine and serotonin reuptake.
Evidence and critical reading
Reported scientific and empirical uses
Reported weight management
Monoamine-reuptake inhibitor promoted for appetite; nonpeptide.
Human evidence
A 203-person randomized obesity trial showed weight-loss effects; it does not establish safety of peptide combinations. The Lancet issued an expression of concern concerning this publication in 2013 (PMID 23561987). This is not a retraction, but the notice must accompany interpretation of this trial.
Preclinical evidence
Central monoamine effects are not peptide pharmacology.
Critical reading and limitations
A 203-participant phase II trial showed weight loss and increased heart rate; it does not establish universal authorization. The Lancet issued an expression of concern concerning this publication in 2013 (PMID 23561987). This is not a retraction, but the notice must accompany interpretation of this trial.
Evidence applies to the exact molecule, formulation, route, population and endpoint studied. Supplier identity, purity and clinical equivalence are unverified.
Source-specific regimens
Descriptive source observations, not individual recommendations.
Regulatory product labeling
Listed regimens preserve source/context. An empty layer means no regimen attributable to this identity was verified in this review; it does not prove universal absence of data.
Human-study exposure
NOT A RECOMMENDATION.Each amount is attributed to the source identified for that entry: regulatory product labeling, human research, or community and practice sources. These source categories have different evidentiary roles. They are not medical advice, not a protocol, not a recommended or safe dose, and not evidence that it works. Do not use them to start, change or stop any treatment. Talk to a qualified healthcare professional.
Reported by Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial.
0.25 / 0.5 / 1 mg · Target amounts in separate arms
- Frequency
- Daily
- Duration
- 24 weeks
- Route
- Oral
- Context
- 203 adults with obesity; assess weight loss and cardiovascular effects together.
- Presentation
- A dosage-form presentation is not specified in the reviewed record.
- Interpretation
- Research exposure: not a prescription or starting regimen. It does not reconstruct protocol titration, exclusions or monitoring. The Lancet issued an expression of concern concerning this publication in 2013 (PMID 23561987). This is not a retraction, but the notice must accompany interpretation of this trial.
PMID18950853 · October 16, 2026
NOT A RECOMMENDATION.Each amount is attributed to the source identified for that entry: regulatory product labeling, human research, or community and practice sources. These source categories have different evidentiary roles. They are not medical advice, not a protocol, not a recommended or safe dose, and not evidence that it works. Do not use them to start, change or stop any treatment. Talk to a qualified healthcare professional.
Empirical handbook
Listed regimens preserve source/context. An empty layer means no regimen attributable to this identity was verified in this review; it does not prove universal absence of data.
Regulation and safety
Jurisdiction-specific regulatory context
Do not claim worldwide approval or prohibition. US/EU and claimed Mexican product status require distinct official verification; unresolved here.
Adverse effects and unknowns
Dry mouth, GI symptoms and heart-rate effects require attention. Interactions with other monoaminergic drugs are pharmacologically plausible; specific product contraindications require local labeling.
Insomnia, GI symptoms and sympathetic effects; serotonergic/sympathomimetic combinations need specific assessment.
Contraindications
See supported safety statements and exact product label; a complete contraindication set has not been established for this catalog material.
A complete list must match the exact authorized product. For experimental materials without verified human labeling, a complete contraindication set is not established here. No list does not mean safety.
Interactions
Only explicitly cited interactions may be asserted; unstudied combinations remain unknown, not interaction-free.
Separate documented interaction, pharmacologic plausibility and unknown interaction. Absence of a blend trial does not establish compatibility.
Studies and trials
Selected studies
No selected studies are attributed in this record.
Trials attributed in the package
No trials are attributed in this record.
Trial registration does not establish efficacy or validate commercial material.
Query candidates; attribution pending
Tesofensine · 13 unfiltered query results, not authenticated trials
Query verification: October 16, 2026
Exact phrase intervention query; first three most recently updated records, not exhaustive. Aliases may be missed and heterogeneous products may appear. The total is the unfiltered registry query count, not authenticated trials. Source-integrity holds are excluded from ordinary listings.
View trial registry queryNCT03149445 · Co-administration of Tesofensine/Metoprolol in Subjects With Prader-Willi Syndrome (PWS)Registry status: CompletedLast update posted: February 26, 2024Query verification: October 16, 2026
NCT03845075 · 48 Weeks, Study to Evaluate Overall Safety and Tolerability of Co-administration of Tesofensine and Metoprolol in Subjects With Hypothalamic Injury-induced Obesity (HIO)Registry status: CompletedLast update posted: February 13, 2024Query verification: October 16, 2026
NCT03488719 · A Study to Examine the Effect of Tesofensine and Metoprolol on the 24-hour Mean Heart RateRegistry status: CompletedLast update posted: February 9, 2024Query verification: October 16, 2026
Source issues and references
References include queries and bibliographic handbook attributions; not all are clinical studies. Human review remains pending.
- PC-TESOFENSINE
PubChem tesofensine (CID 11370864)
October 16, 2026
- PMID18950853
Astrup A, Madsbad S, Breum L, Jensen TJ, Kroustrup JP, Larsen TM.
October 16, 2026
- PMID23561987
October 18, 2026